These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 12422540)

  • 21. ["There are clear criteria for product surveillance studies"].
    Throm S
    MMW Fortschr Med; 2009 Aug; 151(34-35):7. PubMed ID: 19771777
    [No Abstract]   [Full Text] [Related]  

  • 22. Postmarketing drug dosage changes.
    Peck CC
    Pharmacoepidemiol Drug Saf; 2003; 12(5):425-6. PubMed ID: 12899120
    [No Abstract]   [Full Text] [Related]  

  • 23. Pathophysiology of adverse cutaneous drug reactions--applied perceptions: Part II.
    Sehgal VN; Verma P; Bhattacharya SN
    Skinmed; 2012; 10(6):373-83. PubMed ID: 23346666
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Drug nephrotoxicity. A microcomputerized databank of renal involvement and responsible "nephrotox" drugs].
    Hamel JD; Biour M; Cheymol G
    Therapie; 1988 May; 43(3):211-7. PubMed ID: 3420569
    [No Abstract]   [Full Text] [Related]  

  • 25. [Evaluation of medication side-effects from an economic perspective].
    Segura O; Maldonado C
    Biomedica; 2003 Dec; 23(4):401-7. PubMed ID: 14968918
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prescription for trouble: common drugs, hidden dangers. Tens of people are at risk.
    Consum Rep; 2006 Jan; 71(1):34-9. PubMed ID: 16491527
    [No Abstract]   [Full Text] [Related]  

  • 27. The downside of a drug-crazed world.
    Neilson EG
    J Am Soc Nephrol; 2006 Oct; 17(10):2650-1. PubMed ID: 16959823
    [No Abstract]   [Full Text] [Related]  

  • 28. [Retrospective analysis of adverse cutaneous drug reactions in patients hospitalized in Department of Dermatology and Venereology of Pomeranian Medical University in 1996-2006].
    Kacalak-Rzepka A; Klimowicz A; Bielecka-Grzela S; Załuga E; Maleszka R; Fabiańczyk H
    Ann Acad Med Stetin; 2008; 54(2):52-8. PubMed ID: 19374232
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Multiple drug allergy in patients with cutaneous adverse drug reactions diagnosed by in vitro drug-induced interferon-gamma release.
    Halevy S; Grossman N
    Isr Med Assoc J; 2008 Dec; 10(12):865-8. PubMed ID: 19160944
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Drug surveillance as seen by the general practitioner. Apropos of a survey of 4175 physicians].
    Begaud B; Haramburu F; Péré JC; Delmas N; Lorson B; Albin H
    Therapie; 1984; 39(5):453-7. PubMed ID: 6506000
    [No Abstract]   [Full Text] [Related]  

  • 31. Importance and challenges of studying marketed drugs: what is a phase IV study? Common clinical research designs, registries, and self-reporting systems.
    Glasser SP; Salas M; Delzell E
    J Clin Pharmacol; 2007 Sep; 47(9):1074-86. PubMed ID: 17766697
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Misuse of drugs: conclusions of the pharmacovigilance workshops at La Baule, France].
    Fermont I;
    Therapie; 2002; 57(3):283-8. PubMed ID: 12422543
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The file of side effects to the skin: a guide to drug eruptions.
    Bruinsma W
    Semin Dermatol; 1989 Sep; 8(3):141-3. PubMed ID: 2534879
    [No Abstract]   [Full Text] [Related]  

  • 34. [Side effects of drugs on the skin].
    Bork K
    Med Klin (Munich); 1992 Jun; 87(6):329-33. PubMed ID: 1386137
    [No Abstract]   [Full Text] [Related]  

  • 35. [Imputability in drug monitoring. Principles of the balanced drug reaction assessment method and principal errors to avoid].
    Lagier G; Vincens M; Castot A
    Therapie; 1983; 38(3):303-18. PubMed ID: 6612667
    [No Abstract]   [Full Text] [Related]  

  • 36. Scientific challenges in postmarketing surveillance of ocular adverse drug reactions.
    Fraunfelder FW; Fraunfelder FT
    Am J Ophthalmol; 2007 Jan; 143(1):145-149. PubMed ID: 17188050
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Incidence of allergy caused by external drugs in the light of frequency of their use in individual medical prescriptions].
    Rudzki E; Zakrzewski Z; Kleniewska D; Pietura A
    Przegl Dermatol; 1976; (6 Suppl):187-90. PubMed ID: 146225
    [No Abstract]   [Full Text] [Related]  

  • 38. Toward improved adverse event/suspected adverse drug reaction reporting.
    Gross R; Strom BL
    Pharmacoepidemiol Drug Saf; 2003 Mar; 12(2):89-91. PubMed ID: 12642971
    [No Abstract]   [Full Text] [Related]  

  • 39. [Surveillance studies criticized. A marketing effort for expensive drugs? "Not throwing the baby out with the bath water" (interview by Dr. Beate Schumacher)].
    Selbmann HK
    MMW Fortschr Med; 2009 Aug; 151(34-35):6. PubMed ID: 19771776
    [No Abstract]   [Full Text] [Related]  

  • 40. [Can the structural formula of a drug verify the risk of contact allergy?].
    Karlberg AT; Nilsson JL; Wahlberg JE
    Lakartidningen; 1992 Sep; 89(40):3259-61. PubMed ID: 1405938
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.